Gulmez S Ezgi, Tulunay F Cankat, Beder Sumru, Kayacan Oya, Karnak Demet
Department of Pharmacology and Clinical Pharmacology, Medical School of Ankara University, 06100 Sihhiye, Ankara, Turkey.
Respir Med. 2006 May;100(5):828-34. doi: 10.1016/j.rmed.2005.09.002. Epub 2005 Oct 6.
Dipyrone (Novalgin) is an effective analgesic, antipyretic agent also with spasmolytic effects on various types of smooth muscles. It has recently been reported that dipyrone relaxes tracheal smooth muscle of guinea pig. In this present study, we aimed to investigate whether this and previously reported in vitro results have any consequences on the respiratory function of normal healthy volunteers and chronic obstructive pulmonary disease (COPD) patients.
In this one-centered, non-randomized, non-comparative, open labelled study, 15 normal healthy volunteers and 15 stable COPD patients, with partially reversible bronchospasm, diagnosed according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria were enrolled in the study at the time they had any indication of dipyrone use. The spirometric tests were performed by a portable notebook and Medikro Spiro2000 spirometry programme-software 1.6 version, before 30, 60, 90, and 120 min after 20 mg/kg of orally dipyrone intake. Groups were compared with the General Linear Model Repeated Measures analysis of variance.
None of the spirometric parameters evaluated showed any significant differences when compared with the baseline values in both groups.
While dipyrone had no bronchodilator effects on either COPD patients or normal volunteers, it also did not impair the spirometric parameters. Since COPD is a disease characterized by a progressive and largely irreversible airflow limitation, dipyrone has no observable bronchodilator effect. However, since dipyrone does not impair the pulmonary function, it can be used safely in COPD patients when there is an indication.
安乃近是一种有效的镇痛药和解热药，对各种类型的平滑肌也有解痉作用。最近有报道称，安乃近可使豚鼠气管平滑肌松弛。在本研究中，我们旨在调查这一结果以及先前报道的体外实验结果是否会对正常健康志愿者和慢性阻塞性肺疾病（COPD）患者的呼吸功能产生任何影响。
在这项单中心、非随机、非对照、开放标签的研究中，15名正常健康志愿者和15名稳定期COPD患者（根据慢性阻塞性肺疾病全球倡议组织（GOLD）标准诊断为部分可逆性支气管痉挛）在有任何使用安乃近指征时被纳入研究。在口服20mg/kg安乃近前以及服药后30、60、90和120分钟，使用便携式笔记本电脑和Medikro Spiro2000肺功能仪软件1.6版本进行肺功能测试。采用一般线性模型重复测量方差分析对各组进行比较。
与两组的基线值相比，所评估的任何肺功能参数均未显示出任何显著差异。
虽然安乃近对COPD患者和正常志愿者均无支气管扩张作用，但也未损害肺功能参数。由于COPD是以进行性且在很大程度上不可逆的气流受限为特征的疾病，安乃近没有可观察到的支气管扩张作用。然而，由于安乃近不会损害肺功能，在有指征时可安全地用于COPD患者。
